Smaller scale New Zealand dairy farmers: long term plans and key challenges

Farmer wellbeing has been defined as “a dynamic process that gives people a sense of how their lives are evolving” (Nimpagariste & Culver, 2010). In order to support and enhance the wellbeing of farmers in New Zealand, the farmers’ goals, future plans and challenges to their plans all need to be understood. A particular group of interest is smaller scale dairy farmers. The average size of dairy farms in developed agricultural nations is increasing and New Zealand is no different. A high proportion (62%) of NZ dairy herds are smaller scale, milking less than 400 cows at peak. Their wellbeing, now and in the future, is important to the New Zealand dairy industry as a whole. Consequently, the aim of this study is to develop an understanding of smaller-scale dairy farmers’ future goals, plans and challenges so that recommendations can be made to enhance and support their wellbeing in the future. Farms who peak milked less than 400 cows were surveyed via telephone. A total of 346 surveys were completed, in Taranaki (n=103), the Waikato (n=144) and Northland (n=99). The majority of respondents’ were owner-operators (75%), male (67%), born and bred in a rural area (79%), and between 40 and 60 years old (57%). Overall, the mean farm size was 97ha, with 240 cows producing 86,789kgMS with 0.83 of a full time employee. Respondents’ had high (67%) equity levels in their businesses and a third (35%) had non-farming investments. Farmers’ most likely future investments were related to their current farming business, that is reducing debt to very low levels and increasing production by more than 10%. Based on farmers future plans and challenges reported and discussed in this study, it is clear the smaller scale dairy farmers would like knowledge and assistance in five key areas; succession, regulation and compliance, staff, technology and cash-flow/profitability. This report concludes with suggestions for each of these areas, which has the potential to maintain or increase the wellbeing of smaller scale dairy farmers in New Zealand. [Executive summary]DairyNZ Ltd, Ministry for Primary Industry (NZ

Fractional Brownian Motion as a Differentiable Generalized Gaussian Process

Brownian motion can be characterized as a generalized random process and, as such, has a generalized derivative whose covariance functional is the delta function. In a similar fashion, fractional Brownian motion can be interpreted as a generalized random process and shown to possess a generalized derivative. The resulting process is a generalized Gaussian process with mean functional zero and covariance functional that can be interpreted as a fractional integral or fractional derivative of the delta-function.Brownian motion, fractional Brownian motion, fractional derivative, covariance functional, delta function, generalized derivative, generalized Gaussian process

The association between life events, social support, and antibody status following thymus-dependent and thymus-independent vaccinations in healthy young adults

This study determined whether stressful life events and social support were related to antibody status following both thymus-dependent and thymus-independent vaccinations. Life events in the previous year and customary social support were measured in 57 healthy students at baseline. Antibody status was also assessed at baseline and at five weeks and five months following vaccination with the trivalent influenza vaccine and the meningococcal A+C polysaccharide vaccine. Taking into account baseline antibody titre, high life events scores prior to vaccination were associated with lower responses to the B/Shangdong influenza strain at both five weeks and five months and meningococcal C at five weeks. Life events scores were not associated with response to the other two influenza viral strains nor response to meningococcal A. Those with high social support scores had stronger 5-week and 5-month antibody responses to the A/Panama influenza strain, but not to any of the other strains. These associations could not be accounted for by demographic or health behaviour factors, and also emerged from analyses comparing those who exhibited a four-fold increase in antibody titre from baseline with those who did not. Life events and social support were related to antibody status following influenza vaccination in distinctive ways that may be partly determined by vaccine novelty and prior naturalistic exposure. Life events also predicted poor antibody response to meningococcal C polysaccharide vaccination after previous meningococcal C conjugate vaccination. Neither psychosocial factor was associated with response to primary meningococcal A polysaccharide vaccination

Observation of enhanced defect emission and excitonic quenching from spherically indented ZnO

The influence of spherical nanoindentation on the band edge and deep level emission of single crystal c-axis ZnO has been studied by cathodoluminescence(CL) spectroscopy and monochromatic imaging. Excitonic emission is quenched at the indent site and defect emission in the range of 450–720nm is enhanced.The authors wish to acknowledge the Australian Research Council for its financial support

Measles virus causes immunogenic cell death in human melanoma

Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma. This study demonstrates the efficacy of MV against human melanoma. It is increasingly recognised that an essential component of therapy with OV is the recruitment of host anti-tumour immune responses, both innate and adaptive. MV-mediated melanoma cell death is an inflammatory process, causing the release of inflammatory cytokines including type-1 interferons and the potent danger signal HMGB1. Here, using human in vitro models, we demonstrate that MV enhances innate antitumour activity, and that MV-mediated melanoma cell death is capable of stimulating a melanoma-specific adaptive immune response

Innovation and Tradition: A Survey of Intellectual Property and Technology Legal Clinics

For artists, nonprofits, community organizations and small-business clients of limited means, securing intellectual property (IP) rights and getting counseling involving patent, copyright and trademark law are critical to their success and growth. These clients need expert IP and technology legal assistance, but very often cannot afford services in the legal marketplace. In addition, legal services and state bar pro bono programs have generally been ill-equipped to assist in these more specialized areas. An expanding community of IP and Technology clinics has emerged across the country to meet these needs. But while law review articles have described and examined other sectors of clinical legal education, there has not been an article to date that examines the rise and the role of such clinics. This is an important need to fill. With student and client and law firm demand for IP and Technology clinics, law schools want information about existing programs, and existing programs want information about the innova- tions of other clinics and collaboration opportunities. In addition, the traditional clinical community wants to ensure that these new pro- grams build on the strengths of the original founding clinics. This article distills the results of a comprehensive survey of seventy-two distinct IP and Technology clinics into themes that analyze the focus and aspirations of this new clinical community. It takes stock of what IP and Technology clinics were founded to accomplish, how and what they are teaching students, and what clients and missions drive them. It highlights some individual innovations to inspire the community to continue to grow and change. It concludes by assessing what these clinics accomplish, how they are faring on these goals and the role they may play in the future of clinical legal education and experiential learning more generally

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.

BACKGROUND: High rates of second-line antiretroviral treatment (ART) failure are reported. The association with resistance and nonadherence on switching to second-line ART requires clarification. METHODS: Using prospectively collected data from patients in South Africa, we constructed a cohort of patients switched to second-line ART (1 January 2003 through 31 December 2008). Genotyping and drug concentrations (lamivudine, nevirapine, and efavirenz) were measured on stored samples preswitch. Their association with viral load (VL) <400 copies/mL by 15 months was assessed using modified Poisson regression. RESULTS: One hundred twenty-two of 417 patients (49% male; median age, 36 years) had genotyping (n = 115) and/or drug concentrations (n = 80) measured. Median CD4 count and VL at switch were 177 cells/µL (interquartile range [IQR], 77-263) and 4.3 log10 copies/mL (IQR, 3.8-4.7), respectively. Fifty-five percent (n = 44/80) had subtherapeutic drug concentrations preswitch. More patients with therapeutic vs subtherapeutic ART had resistance (n = 73): no major mutations (3% vs 51%), nonnucleoside reverse transcriptase inhibitor (94% vs 44%), M184V/I (94% vs 26%), and ≥ 1 thymidine analogue mutations (47% vs 18%), all P = .01; and nucleoside reverse transcriptase inhibitor (NRTI) cross-resistance mutations (26% vs 13%, P = .23). Following switch, 68% (n = 83/122) achieved VL <400 copies/mL. Absence of NRTI mutations and subtherapeutic ART preswitch were associated with failure to achieve VL <400 copies/mL. CONCLUSIONS: Nonadherence, suggested by subtherapeutic ART with/without major resistance mutations, significantly contributed to failure when switching regimen. Unresolved nonadherence, not NRTI resistance, drives early second-line failure